M

    Mustang Bio Inc (MBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    +0.00 (+0.02%)

    Market Cap: $4.07M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(14/29)
    Avg Surprise
    -8.36%
    Streak
    2 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.16N/AN/ABeat+15.8%
    Mar 26
    		$-0.14N/AN/ABeat+85.1%
    Dec 25
    		$-0.07N/AN/ABeat-102.0%
    Sep 25
    		$-0.07N/AN/ABeat+96.5%
    Jun 25
    		$-0.19$0.00N/ABeat+98.4%
    Mar 25
    		$-0.95$0.00N/ABeat+95.9%
    Dec 24
    		$3.63N/A+145.38%Beat+522.1%
    Sep 24
    		$-2.00N/A+69.23%Beat+97.1%
    Jun 24
    		$-12.00$-7.00-71.43%Miss+88.0%
    Mar 24
    		$-23.00$-11.00-109.09%Miss+77.7%
    Dec 23
    		$-0.86$-1.33+35.34%Beat+68.1%
    Sep 23
    		$-69.81$-77.50+9.92%Beat+48.3%
    Jun 23
    		$-100.00$-85.75-16.62%Miss+29.8%
    Mar 23
    		$-103.00$-150.50+31.56%Beat+31.3%
    Dec 22
    		$-2.70$-2.89+6.57%Beat-1127.3%
    Sep 22
    		$-135.00$-147.50+8.47%Beat+5.3%
    Jun 22
    		$-142.50$-155.00+8.06%Beat-18.8%
    Mar 22
    		$-150.00$-140.00-7.14%Miss-5.3%
    Dec 21
    		$-0.22$-0.19-15.79%Miss+31.3%
    Sep 21
    		$-142.50$-127.50-11.76%Miss+17.4%
    Jun 21
    		$-120.00$-142.50+15.79%Beat+50.0%
    Mar 21
    		$-142.50$-127.50-11.76%Miss-50792.9%
    Dec 20
    		$-0.32$-0.21-52.38%Miss+99.9%
    Sep 20
    		$-172.50$-180.00+4.17%Beat+8.0%
    Jun 20
    		$-240.00$-200.00-20.00%Miss-10.3%
    Mar 20
    		$-0.28$-0.31+9.68%Beat+17.6%
    Dec 19
    		$-307.50$-197.50-55.70%Miss+6.8%
    Sep 19
    		$-187.50$-197.50+5.06%Beat+10.7%
    Jun 19
    		$-217.50$-187.50-16.00%Miss-52.6%
    Mar 19
    		$-0.34$-0.36+5.56%Beat+99.8%
    Dec 18
    		$-330.00$-202.50-62.96%Miss-53998.4%
    Sep 18
    		$-210.00$-187.50-12.00%Miss-77677.8%
    Jun 18
    		$-142.50$-187.50+24.00%Beat-67757.1%
    Mar 18
    		$-180.00$-172.50-4.35%Miss-128471.4%
    Dec 17
    		$-0.61$-0.24-154.17%Miss-
    Sep 17
    		$-0.27N/AN/ABeat-
    Jun 17
    		$-0.21N/AN/ABeat-
    Mar 17
    		$-0.14N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.21EV/EBITDA-0.14x
    Price/FCF-0.80xFCF Yield-124.60%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-58.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    Beta2.05Avg Volume25.77K
    52-Week High$1.8552-Week Low$0.53

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.56
    SMA 20$0.58
    SMA 50$0.62
    SMA 200$0.84
    EMA 10$0.56
    EMA 20$0.57
    EMA 50$0.61
    EMA 200$0.87

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 21.9+DI: 11.1-DI: 24.9

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down8.0
    PSAR$0.62

    Bollinger Bands

    Upper Band$0.62
    Lower Band$0.53
    %B Position1552%(Upper)
    Band Width0.06

    RSI (14-Day)

    Neutral
    36.2

    Momentum Oscillators

    Stoch %K7.4
    Stoch %D9.9
    Williams %R-92.1
    ROC (10d)-9.5%
    Momentum-0.06
    CCI (20d)-147.4
    MFI (14d)35.4

    Volatility Measures

    ATR (14d)$0.03(5.9%)
    StdDev (20d)0.02
    Hist Vol37.7%(Moderate)

    Volume Flow

    VWAP$0.54
    OBV296.8M
    AD Line-258.8M
    CMF (20d)-0.073

    Volume Metrics

    Avg Vol (20d)23.4K
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.58

    Pivot Points

    R3$0.57
    R2$0.56
    R1$0.55
    Pivot Point$0.54
    S1$0.53
    S2$0.52
    S3$0.51

    Advanced Oscillators

    TSI-19.34
    Ultimate Osc36.7
    KST-94.58

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.99M$0$0$0$2.88M$0
    Cost of Revenue$0$0N/A$0$0$0$996,000$0$0$0$363,000$0
    Gross Profit$0$0N/A$0$0$0$996,000$0$0$0$2.52M$0
    Operating Expenses$1.17M$1.06M$670,000$624,000$885,000$253,000$1.02M$1.46M$8.54M$5.23M$8.74M$10.31M
    R&D$224,000$178,000$-317,000$-333,000$98,000$-964,000$197,000$57,000$4.36M$3.80M$6.68M$9.53M
    SG&A$946,000$880,000$987,000$957,000$787,000$1.22M$-223,000$1.40M$1.53M$1.43M$2.18M$2.13M
    Operating Income$-1,170,000$-1,058,000$-670,000$-624,000$-885,000$-253,000$-1,017,000$-1,457,000$-8,540,000$-5,231,000$-8,741,000$-10,307,000
    Interest Income$98,000$103,000$132,000$156,000$123,000$100,000$65,000$47,000$27,000$40,000$123,000$115,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$-3,000$4,000
    Income Before Tax$-1,072,000$-955,000$-538,000$-468,000$-762,000$-153,000$-952,000$-1,410,000$-8,199,000$-5,191,000$-8,616,000$-10,058,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,072,000$-955,000$-538,000$-468,000$-762,000$-153,000$-952,000$-1,410,000$-8,199,000$-5,191,000$-8,616,000$-10,058,000
    EBITDA$-1,170,000$-1,058,000$-670,000$-624,000$-885,000$-212,000$-942,000$-1,406,000$-8,225,000$-4,535,000$-8,379,000$-9,802,000
    EBIT$-1,170,000$-1,058,000$-670,000$-624,000$-885,000$-253,000$-1,017,000$-1,457,000$-8,226,000$-5,231,000$-8,742,000$-10,169,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MBIO

    News

    MUSTANG BIO, INC. Q2 2026: Net income $(1.07)M, EPS $(0.16) — 10-Q Summary

    MUSTANG BIO, INC. (MBIO) reported a wider net loss in Q2 2026, with net income (loss) of $(1.07)M compared to $(0.76)M in Q2 2025. Diluted loss per share was $(0.16), an improvement from $(0.19) in the previous year, with no product revenue reported. The company highlighted pipeline progress with IND acceptance for MB-109 and Orphan Drug Designations for MB-108 and MB-101 from the FDA.

    TradingView•8/6/26•
    Neutral

    Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

    Mustang Bio, Inc. announced its financial results for the second quarter and first six months ended June 30, 2026. For the second quarter, the company reported a net loss of $1.07 million, an increase from $0.762 million in the prior year, with a basic and diluted loss per share of $0.16. Over the six-month period, the net loss grew to $2.03 million, up from $0.915 million a year ago, resulting in a basic and diluted loss per share of $0.30.

    www.marketscreener.com•8/6/26•
    Somewhat-Bearish

    Mustang Bio Inc (MBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Mustang Bio Inc (MBIO), noting that no earnings forecast score is currently available for the company. It highlights the average score for the Biotechnology & Medical Research industry, which is 8.10, and includes a peer comparison of analyst ratings for other

    TradingKey•8/6/26•
    Neutral

    Mustang Bio Q2 net loss widens 41% to $1.07 million

    Mustang Bio reported a Q2 net loss of $1.07 million, a 41% increase, with operating loss widening 32% to $1.17 million. Research and development expenses more than doubled, and general and administrative costs rose 20%. The company ended the quarter with $15.2 million in cash and cash equivalents and an accumulated deficit of $400.7 million, while continuing plans for an investigator-sponsored trial.

    Bitget•8/5/26•
    Bearish

    Mustang Bio, Inc. (NASDAQ: MBIO) posts $2.0M loss and faces Nasdaq bid-price warning

    Mustang Bio, Inc. (NASDAQ: MBIO) reported a net loss of $2.0 million for the first six months of 2026, with an accumulated deficit of $400.7 million, and faces a Nasdaq bid-price warning. The clinical-stage oncology company, which is developing CAR T and oncolytic virus therapies for brain cancers, had cash and cash equivalents of $15.2 million as of June 30, 2026, which management believes will fund operations for at least twelve months. The company is working towards an investigator-sponsored trial for its combination therapy MB-109 in recurrent glioblastoma and high-grade astrocytoma, potentially initiating in Q4 2026.

    Stock Titan•8/5/26•
    Bearish

    Frequently Asked Questions About MBIO

    Does MBIO pay dividends?
    Mustang Bio Inc (MBIO) does not currently pay a regular dividend.
    What is MBIO's market cap?
    Mustang Bio Inc (MBIO) has a market capitalization of $4.07M with a current stock price of $0.54.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In